Most start-up drug development companies search for innovative therapies for diseases. Not Verrica, which began trading on June 15 priced at $16. Instead, Verrica is reaching back to ancient China for a remedy for warts and skin infections made from crushing the bodies of blister beetles.
So why is Verrica trying to get approval for cantharidin, a medicine that’s been used for millennia and is generally regarded as safe?
To read the entire commentary, sign up for a free 7-day trial of IPO Pro, the single most effective IPO investing platform you'll ever need.
